Amgen Archives - World School of Life Sciences IP

Approved Agreement Allowed Validation Concept

Denosumab first interchangeable biosimilars approved by the US FDA

Tanu Goyal April 17, 2024

With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count

Generics for Otezla® to be out in the United States in February 2028

Tanu Goyal September 14, 2023

Generics for Otezla® to be out in the United States in February 2028 Amgen’s oral phosphodiesterase-4 (PDE-4) inhibitor – Otezla® (Apremilast) is approved in the

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.